The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Open accessAbstract
Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androgen ablation therapy. Androgen-sensitive LNCaP cells were kept in androgen-depleted medium for 87 passages. The new LNCaP cell subline established in this manner, LNCaP-abl, displayed a hypersensitive biphasic proliferative response to androgen until passage 75. Maximal proliferation of LNCaP-abl cells was achieved at 0.001 nM of the synthetic androgen methyltrienolone (R1881), whereas 0.01 nM of this compound induced the same effect in parental cells. At later passages (> 75), androgen exerted an inhibitory effect on growth of LNCaP-abl cells. The non-steroidal anti-androgen bicalutamide stimulated proliferation of LNCaP-abl cells. AR protein expression in LNCaP-abl cells increased approximately fourfold. The basal AR transcriptional activity was 30-fold higher in LNCaP-abl than in LNCaP cells. R1881 stimulated reporter gene activity in LNCaP-abl cells even at 0.01 nM, whereas 0.1 nM of R1881 was needed for induction of the same level of reporter gene activity in LNCaP cells. Bicalutamide that acts as a pure antagonist in parental LNCaP cells showed agonistic effects on AR transactivation activity in LNCaP-abl cells and was not able to block the effects of androgen in these cells. The non-steroidal AR blocker hydroxyflutamide exerted stimulatory effects on AR activity in both LNCaP and LNCaP-abl cells; however, the induction of reporter gene activity by hydroxyflutamide was 2.4- to 4-fold higher in the LNCaP-abl subline. The changes in AR activity were associated neither with a new alteration in AR cDNA sequence nor with amplification of the AR gene. Growth of LNCaP-abl xenografts in nude mice was stimulated by bicalutamide and repressed by testosterone. In conclusion, our results show for the first time that the nonsteroidal anti-androgen bicalutamide acquires agonistic properties during long-term androgen ablation. These findings may have repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,122
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 1×
“However, the sequence of the AR in the LNCaP subline does not differ from the sequence of the AR in original Amplification of the AR gene was demonstrated in about 30% advanced prostate tumours (Visakorpi et al, 1995; Cher et al, Koivisto et al, 1997).”
BackgroundMutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Enzymatic synthesis of biotin-labeled polynucleotides: novel nucleic acid affinity probes.
Langer, P. R., Waldrop, A. A., & Ward, D. C. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.6633 · Cited by 1,145
Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P., & Gronemeyer, H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00736.x · Cited by 1,079
Kallioniemi, O., Kallioniemi, A., Piper, J., Isola, J., Waldman, F. M., Gray, J. W., & Pinkel, D. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870100403 · Cited by 1,012
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Koivisto, P. A., Kononen, J., Palmberg, C., Tammela, T. L. J., HYYTINEN, E.-R., Isola, J. J., Trapman, J., Cleutjens, K. B. J. M., Noordzij, M. A., Visakorpi, T., et al. (1997) · PubMed · Cited by 728
Yeh, S., & Chang, C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5517 · Cited by 623
Culig, Z. (1993) · Molecular Endocrinology · doi:10.1210/me.7.12.1541 · Cited by 440
Self-citationActivation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429
Cher, M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B., & Jensen, R. H. (1996) · PubMed · Cited by 391
Androgen receptors in endocrine‐therapy‐resistant human prostate cancer
van der Kwast, T. H., Schalken, J., de Winter, J. A. R., van Vroonhoven, J. C. C., Mulder, E., Boersma, W., & Trapman, J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480206 · Cited by 386
Ikonen, T., Palvimo, J. J., & Jänne, O. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29821 · Cited by 363
Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch, A., CULIG, Z., Radmayr, C., Bartsch, G., Klocker, H., & Hittmair, A. (1995) · PubMed · Cited by 283
Self-citationKokontis, J. M. (1998) · Molecular Endocrinology · doi:10.1210/me.12.7.941 · Cited by 250
Kokontis, J. M., Takakura, K., Hay, N., & Liao, S. (1994) · PubMed · Cited by 248
Androgen-repressed phenotype in human prostate cancer
Zhau, H. Y. E., Chang, S.-M., Chen, B.-Q., Wang, Y., Zhang, H., Kao, C., Sang, Q. A., Pathak, S. J., & Chung, L. W. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15152 · Cited by 231
Androgen receptor gene expression in human prostate carcinoma cell lines.
Tilley, W. D., Wilson, C. M., Marcelli, M., et al. (1990) · PubMed · Cited by 218
Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens
Wilding, G., Chen, M., & Gelmann, E. P. (1989) · The Prostate · doi:10.1002/pros.2990140204 · Cited by 205
Miyamoto, H., Yeh, S., Wilding, G., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7379 · Cited by 203
Lee, C. (1995) · Endocrinology · doi:10.1210/en.136.2.796 · Cited by 197
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita, Y., Hiipakka, R. A., Kokontis, J. M., & Liao, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11802 · Cited by 195
BAG-1L Protein Enhances Androgen Receptor Function
Froesch, B. A., Takayama, S., & Reed, J. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.19.11660 · Cited by 193
Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells1
Jeng, M.-H., Shupnik, M. A., Bender, T. P., Westin, E. H., Bandyopadhyay, D., Kumar, R., Masamura, S., & Santen, R. J. (1998) · Endocrinology · doi:10.1210/endo.139.10.6229 · Cited by 175
Androgen receptor status of lymph node metastases from prostate cancer
Hobisch, A., Čulig, Z., Radmayr, C., Bartsch, G., Klocker, H., & Hittmair, A. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199602)28:2<129::aid-pros9>3.0.co;2-b · Cited by 147
Self-citationVeldscholte, J., Berrevoets, C. A., Zegers, N. D., Van der Kwast, T. H., Grootegoed, J. A., & Mulder, E. (1992) · Biochemistry · doi:10.1021/bi00147a029 · Cited by 139 · cited 2×
“Conve agonistic effects on LNCaP proliferation and AR activity were observed in the presence of another non-steroidal anti-andr bicalutamide (Casodex) (Veldscholte et al, 1992).”
BackgroundČulig, Z., Klocker, H., Eberle, J., Kaspar, F., Hobisch, A., Cronauer, M. V., & Bartsch, G. H. (1993) · The Prostate · doi:10.1002/pros.2990220103 · Cited by 115
Self-citationNakhla, A. M., Romas, N. A., & Rosner, W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.6838 · Cited by 94
Evans, B. A. J., Harper, M. E., Daniells, C., Watts, C. E., Matenhelia, S. S., Green, J., & Griffiths, K. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199603)28:3<172::aid-pros4>3.0.co;2-h · Cited by 89
A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP)
Gibas, Z., Becher, R., KAWINSKI, E., Horoszewicz, J. S., & Sandberg, A. A. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90020-7 · Cited by 79
Čulig, Z., Hobisch, A., Hittmair, A., Cronauer, M. V., Radmayr, C., Zhang, J., Bartsch, G. H., & Klocker, H. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970701)32:2<106::aid-pros5>3.0.co;2-k · Cited by 74
Self-citationČulig, Z., Hobisch, A., Hittmair, A., Cronauer, M. V., Radmayr, C., Bartsch, G. H., & Klocker, H. (1997) · Drugs & Aging · doi:10.2165/00002512-199710010-00005 · Cited by 68
Self-citationHyytinen, E.-R., Thalmann, G., Zhau, H. E., Karhu, R., Kallioniemi, O., Chung, L. W. K., & Visakorpi, T. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.32 · Cited by 68
Gupta, C., Chandorkar, A. K., & Nguyen, A. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(96)03899-3 · Cited by 31
Cited by
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Targeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599
Metadata
- Authors
- Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., & Klocker, H.
- Venue
- British Journal of Cancer
- Published
- 1999-08-27
- Volume
- 81
- Issue
- 2
- Pages
- 242-251
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2095873383
- Cited by
- 409
- References
- 38
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.